J&J explores $20B+ sale of DePuy Synthes orthopedics unit to PE and strategic buyers, pivoting from October spinoff plan. Would reshape global ortho market.

J&J Explores $20 Billion Sale of DePuy Synthes, Pivoting From Spinoff Plan

J&J invests $1B+ in Pennsylvania cell therapy plant, creating 4,500 jobs. Part of $55B US manufacturing push as Carvykti sales doubled to $1.9B.

Johnson & Johnson Bets $1 Billion on Pennsylvania Cell Therapy Plant as Carvykti Sales Near $2 Billion

J&J beats Q4 estimates, raises 2026 guidance to $100B+ sales. But federal judge allows expert testimony linking talc to cancer in 67,500+ lawsuits.

JOHNSON & JOHNSON (JNJ)·Earnings Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Analyst Coverage

Recent News about JOHNSON & JOHNSON

J&J Explores $20 Billion Sale of DePuy Synthes, Pivoting From Spinoff Plan

Johnson & Johnson Bets $1 Billion on Pennsylvania Cell Therapy Plant as Carvykti Sales Near $2 Billion

J&J's $527B Question: Strong Earnings Collide with Major Talc Litigation Ruling

J&J Hit With Record $1.56 Billion Talc Verdict as Bankruptcy Strategy Unravels